Date | Price Target | Rating | Analyst |
---|---|---|---|
2/16/2024 | $62.00 | Outperform | RBC Capital Mkts |
2/6/2024 | $59.00 | Buy | UBS |
12/22/2023 | $50.00 | Buy | H.C. Wainwright |
12/8/2023 | $58.00 | Outperform | Robert W. Baird |
1/24/2023 | $24.00 | Outperform | SVB Securities |
1/4/2023 | $23.00 | Overweight | JP Morgan |
12/2/2022 | $24.00 | Buy | BTIG Research |
10/26/2022 | $158.00 → $27.00 | Neutral → Overweight | Cantor Fitzgerald |
HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl
Reports new positive interim data from the ongoing Phase 1 study of BHV-1300, Biohaven's lead investigational drug from its Molecular Degrader of Extracellular Proteins (MoDE™) platformBHV-1300 demonstrates dose-dependent and rapid IgG reductions within hours of administrationNo SAEs, no severe AEs, most AEs were mild, deemed unrelated to study drug and resolved spontaneouslyNo clinically significant changes in LFTs across any dose cohorts to dateHighlights advances from novel ion channel program targeting Kv7 activation and TRPM3 antagonism across multiple neurological, pain and neuropsychiatric disease indicationsRecently initiated a total of 5 pivotal clinical trials with selective Kv7 ac
-BHV-1510 is a novel trophoblast cell surface antigen-2 (Trop-2) directed antibody drug conjugate (ADC) that has demonstrated a highly differentiated preclinical monotherapy efficacy profile, the potential for broader therapeutic margin than other Trop-2 ADCs currently in development, and synergistic affects when combined with anti-PD1 therapy -Biohaven also entered into a clinical supply agreement with Regeneron to study the combination of BHV-1510 with Regeneron's anti-PD-1 Libtayo® (cemiplimab-rwlc) in the Phase 1/2 clinical trial -Malignancies of epithelial tissue account for the vast majority of all cancers and the advanced or metastatic forms of these carcinomas represent an urgent unm
Cash, cash equivalents, marketable securities and restricted cash totaled approximately $287.6 million on March 31, 2024, which excludes the net proceeds of approximately $247.8 million from Biohaven's public offering completed on April 22, 2024Completed public offering of 6,451,220 Biohaven Ltd. common shares, which included the exercise in full of the underwriters' option to purchase additional shares, at a price to the public of $41.00 per shareReported preliminary summary of data from ongoing single ascending dose (SAD) study with the lead asset from Biohaven's Molecular Degrader of Extracellular Proteins (MoDE™) platform, BHV-1300FDA granted rare pediatric disease designation for the Co
SC 13G/A - Biohaven Pharmaceutical Holding Co Ltd. (0001689813) (Subject)
SC 13G/A - Biohaven Pharmaceutical Holding Co Ltd. (0001689813) (Subject)
SC 13G/A - Biohaven Pharmaceutical Holding Co Ltd. (0001689813) (Subject)
SC 13G/A - Biohaven Pharmaceutical Holding Co Ltd. (0001689813) (Subject)
Novel first-in-class, brain-penetrant, dual inhibitor of TYK2/JAK1 offers wide therapeutic index with TYK2 inhibition and high selectivity for JAK1 inhibition without the severely limiting adverse class effects of JAK2/JAK3 inhibitorsExclusive license covers global rights excluding China regionBiohaven anticipates initiating Phase 1 clinical development in 2023NEW HAVEN, Conn., March 22, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) today announced that it acquired global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1) for the treatment of brain disorders. BHV-8000 (previously TLL-041) was
Full-Year 2022 Revenues of $100.3 Billion, An All-Time High for Pfizer, Reflecting 30% Operational Growth Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 2% Operationally Strong Fourth-Quarter 2022 Revenues of $24.3 Billion, Reflecting 13% Operational Growth Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 5% Operationally Full-Year 2022 Reported Diluted EPS(2) of $5.47, Up 42% Year-Over-Year, and Adjusted Diluted EPS(3) of $6.58, Up 62% Year-Over-Year, Both of Which Represent All-Time Highs for Pfizer Fourth-Quarter 2022 Reported Diluted EPS(2) of $0.87, Up 48% Year-Over-Year, and Adjusted Diluted EPS(3) of $1.14, Up 45% Year-Over-Y
Solid Third-Quarter 2022 Revenues of $22.6 Billion Due to Exceptionally Strong Growth Achieved in the Prior-Year Quarter, Revenues Declined 2% Operationally Excluding Contributions from Paxlovid and Comirnaty(1), Revenues Grew 2% Operationally Third-Quarter 2022 Reported Diluted EPS(2) of $1.51, Reflecting 6% Growth Over Third-Quarter 2021, Including a $0.15 Incremental Benefit in the Current Period Related to Tax Resolutions for Multiple Years Impacting Both Reported(2) and Adjusted(3) Diluted EPS Third-Quarter 2022 Adjusted Diluted EPS(3) of $1.78, Reflecting 40% Growth Over Third-Quarter 2021; Excluding Foreign Exchange Impacts, Adjusted Diluted EPS(3) Grew 44% Raises Lower
Antitrust approvals have been granted by the relevant governing authorities, including the Federal Trade Commission ("FTC"), with respect to the previously announced Pfizer Inc. acquisition of Biohaven Pharmaceutical Holding Company Ltd.; preliminary proxy statement has been filed with the SECNURTEC® ODT (rimegepant) TRx volumes grew 11% and net product revenue was $194 million, up sequentially 57%Anticipated closing of the merger agreement necessitates accounting of derivative losses in the amount of $1.57 per share resulting in a total second quarter reported net loss of $6.21 per share; non-GAAP adjusted net loss1 for the second quarter was $3.82 per shareFeatured 31 new and encore presen
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
RBC Capital analyst Leonid Timashev reiterates Biohaven (NYSE:BHVN) with a Outperform and maintains $59 price target.
HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:BHVN) with a Buy and maintains $59 price target.
Cantor Fitzgerald analyst Charles Duncan reiterates Biohaven (NYSE:BHVN) with a Overweight.
U.S. stocks were lower, with the Dow Jones index falling around 1% on Thursday. Shares of HP Inc. (NYSE:HPQ) rose sharply during Thursday's session following better-than-expected second-quarter financial results. Net revenue declined 0.8% Y/Y to $12.8 billion, beating the consensus of $12.6 billion. Adjusted EPS rose 4% Y/Y to 82 cents, surpassing the street view of 81 cents, according to data from Benzinga Pro. HP shares climbed 12.5% to $36.94 on Thursday. Here are some other big stocks recording gains in today's session. Latam Logistic Properties, S.A. (NYSE:LPA) shares jumped 61% to $53.35. Foot Locker, Inc. (NYSE:FL) rose 25.9% to $28.35 following a first-quarter earn
HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl
Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights (excluding China)Appointed Nick Kozauer, M.D. as SVP of Clinical Development and Regulatory Strategy following his tenure as Director of the Division of Neurology 2 in the Office of New Drugs of the U.S. Food and Drug AdministrationTaldefgrobep alfa granted Fast Track Designation in SMADriving strong and consistent progress across six robust drug development platforms in 2023:in Kv7 activation, targeting Phase 2/3 study start in focal epilepsy and bipolar disorder in the second half of 2023;Phase 1 study initiation planned with potentially fi
NEW HAVEN, Conn., April 17, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company, today announced that Nick Kozauer, M.D. has joined its executive leadership team as Senior Vice President for Clinical Development and Regulatory Strategy. Dr. Kozauer comes to Biohaven after an accomplished career at the U.S. Food and Drug Administration (FDA) where he served in positions of increasing responsibility, most recently as Director of the Division of Neurology 2 in the Office of New Drugs. During his tenure at the FDA, Dr. K
NEW HAVEN, Conn., Dec. 6, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), a biopharmaceutical company with a portfolio of commercial and innovative, late-stage product candidates targeting neurological diseases including rare disorders, today announced that the Board of Directors unanimously elected Vlad Coric, MD to the role of Chairman of the Board of Directors following the retirement of Declan Doogan, MD, effective immediately. The company also announced the appointment of Matthew Buten to the role of Chief Financial Officer (CFO) effective by December 20, 2021, following the retirement of CFO James Engelhart. Both Dr. Doogan and Mr. Engelhart will continue
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
4 - Biohaven Ltd. (0001935979) (Issuer)
RBC Capital Mkts initiated coverage of Biohaven with a rating of Outperform and set a new price target of $62.00
UBS initiated coverage of Biohaven with a rating of Buy and set a new price target of $59.00
H.C. Wainwright initiated coverage of Biohaven with a rating of Buy and set a new price target of $50.00
Robert W. Baird initiated coverage of Biohaven with a rating of Outperform and set a new price target of $58.00
8-K - Biohaven Ltd. (0001935979) (Filer)
424B7 - Biohaven Ltd. (0001935979) (Filer)
S-8 - Biohaven Ltd. (0001935979) (Filer)
8-K - Biohaven Ltd. (0001935979) (Filer)